Kidney Cancer Clinical Trial

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Summary

This phase II/III trial compares the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery in treating patients with upper urinary tract cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as methotrexate, vinblastine, doxorubicin, cisplatin, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Durvalumab in combination with chemotherapy before surgery may enhance the shrinking of the tumor compared to chemotherapy alone.

View Full Description

Full Description

PRIMARY OBJECTIVES:

I. To compare event-free survival (EFS) between patients with upper tract urothelial cancer (UTUC) randomized to neoadjuvant accelerated methotrexate, vinblastine, adriamycin, cisplatin (aMVAC) alone or in combination with durvalumab. (Cisplatin eligible patients [Arms A and B]) II. Evaluation of pathologic complete response at radical nephroureterectomy (RNU) (pathologic complete response [pCR], pT0N0/ Nx). (Cisplatin ineligible patients [Arm C]).

SECONDARY OBJECTIVES:

I. To assess pathologic complete response (pCR) at surgery. (Cisplatin eligible cohort) II. Event-free survival (EFS) will be evaluated for the cisplatin ineligible cohort as a secondary endpoint. (Cisplatin ineligible cohort) III. Overall survival in all, and by post chemotherapy response (ypCR, yp =< T1N0, yp >= T2Nany). (All patients) IV. To evaluate disease-free survival (DFS) in each arm of the trial separately. (All patients) V. To evaluate cancer-specific survival of patients in each arm of the trial separately. (All patients) VI. To evaluate renal function outcomes following systemic treatment and following surgery ([RNU) in each arm of the trial separately. (All patients) VII. To evaluate safety and tolerability of neoadjuvant aMVAC alone or in combination with durvalumab prior to RNU. (All patients)

OUTLINE: Patients eligible for cisplatin are randomized to Arms A or B. Patients ineligible for cisplatin are assigned to Arm C.

ARM A: Patients receive durvalumab intravenously (IV) over 60 minutes on day 1 of chemotherapy cycles 1 and 3. Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery.

ARM B: Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery.

ARM C: Patients receive durvalumab IV over 60 minutes on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery.

Patients also undergo tissue biopsy and blood sample collection on study, and computed tomography (CT) or magnetic resonance imaging (MRI) throughout the trial.

After completion of study treatment, patients are followed up within 30 days and then every 3-6 months for up to 5 years from study entry.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

STEP 1 REGISTRATION AND RANDOMIZATION
Patients must be >= 18 years of age
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible

Patient must have a diagnosis of high grade upper tract urothelial carcinoma proven by biopsy within 12 weeks (84 days) prior to registration/randomization with one of the following:

Upper urinary tract mass on cross-sectional imaging or

Tumor directly visualized during upper urinary tract endoscopy before referral to medical oncology

NOTE: Biopsy is standard of care (SOC) and required for enrollment to study. This is vital for best practice
Leukocytes >= 3,000/mcL (obtained =< 14 days prior to registration/randomization)
Platelets >= 100,000/mcL (obtained =< 14 days prior to registration/randomization)
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (or =< 2.5 x ULN for patients with Gilbert's disease) (obtained =< 14 days prior to registration/randomization)
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN (obtained =< 14 days prior to registration/randomization)

Hemoglobin (Hgb) >= 9 g/dL (obtained =< 14 days prior to registration/randomization)

NOTE: Packed red blood transfusion is allowed to achieve this parameter as per treating investigator

Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration/randomization are eligible for this trial

NOTE: These patients must be stable on their anti-retroviral regimen with evidence of at least two undetectable viral loads within the past 6 months on the same regimen; the most recent undetectable viral load must be within the past 12 weeks. They must have a CD4 count of greater than 250 cells/mcL over the past 6 months on this same anti-retroviral regimen and must not have had a CD4 count < 200 cells/mcL over the past 2 years, unless it was deemed related to the cancer and/or chemotherapy induced bone marrow suppression. They must not be currently receiving prophylactic therapy for an opportunistic infection and must not have had an opportunistic infection within the past 6 months
NOTE: For patients who have received chemotherapy in the past 6 months, a CD4 count < 250 cells/mcL during chemotherapy is permitted as long as viral loads were undetectable during this same chemotherapy. They must have an undetectable viral load and a CD4 count >= 250 cells/mcL within 7 days of registration/randomization

For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated

NOTE: Testing for HIV, hepatitis B or hepatitis C is not required unless clinically indicated
Patients with a history of hepatitis C virus (HCV) infection must have been treated and have undetectable viral load. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
Patient must have a body weight of > 30 kg
Patient must have life expectancy of >= 12 weeks

Patient must have creatinine clearance > 15 ml/min as by Crockroft-Gault formula or 24-hour creatinine clearance within 28 days prior to registration/randomization

NOTE: Patients will be assigned to cisplatin-ineligible and cisplatin-eligible cohorts based on their creatinine clearance, Eastern Cooperative Oncology Group (ECOG) performance status, and grade (if any) of peripheral neuropathy and/or hearing loss in keeping with SOC cisplatin contraindications. Patients that are cisplatin-eligible will be randomized to either Arm A or Arm B

Patients that meet any of the following criteria will be registered and assigned to the cisplatin-ineligible Arm C if they meet other eligibility criteria:

Creatinine clearance > 15 ml/min and =< 50 ml/min or hearing loss grade >= 3, or neuropathy >= 2, or ECOG PS 2
Patient must have an absolute neutrophil count (ANC) >= 1,000/mcL obtained =< 14 days prior to registration
Patient must have ECOG performance status 0-2

Patients that meet the following criteria will be randomized to the cisplatin-eligible Arm A or Arm B:

Patient must have creatinine clearance of > 50ml/min, PS ECOG 0-1, absence of hearing loss grade >= 3, and/or neuropathy >= 2
Patient must have an absolute neutrophil count (ANC) >= 1,500/mcL obtained =< 14 days prior to randomization
Patient must have left ventricular ejection fraction (LVEF) >= 50% by (either multigated acquisition scan [MUGA] or 2-D echocardiogram) obtained within obtained within 28 days prior to randomization

Exclusion Criteria:

Patients must not have any component of small cell/neuroendocrine carcinoma. Other variant histologic types are permitted provided the predominant (>= 50%) subtype is urothelial carcinoma
Patients must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy. A patient of childbearing potential is defined as any patient, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
Patients of childbearing potential and sexually active patients must not expect to conceive or father children, either by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse from the time of registration, while on study treatment and for at least 6 months after the last dose of protocol treatment

Patients must have no evidence of metastatic disease or clinically enlarged regional lymph nodes (>= 1.5 cm short axis) on imaging required within 28 days prior to registration (Non-regional findings >=1.5 cm short axis that in the opinion of the investigator are not concerning for involvement based on radiographic characteristics, chronicity, avidity on positron emission tomography (PET) or other imaging or other criteria can be eligible based on investigator discretion).

NOTE: Patients with elevated alkaline phosphatase, calcium or suspicious bone pain/tenderness can also undergo baseline bone scans to evaluate for bone metastasis at the discretion of local provider.

Patient must meet below criteria for prior/current malignancy history:

Non-urothelial cancer malignancy history:

Patient must not have another active (or within two years) second malignancy other than resected non-melanoma skin cancers, resected in situ breast, cervical or other in situ carcinoma, and either clinically insignificant per the investigator (e.g. =< Gleason 3+4) on active surveillance (or watchful waiting) or previously treated prostate cancer with no rising prostate specific antigen (PSA) and no plan to treat

NOTE: Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. Patients in whom concomitant or prior bladder/urethra predominant (>= 50%) urothelial carcinoma have been surgically resected and demonstrated to be only non-invasive cancer (< cT1N0) are eligible regardless of time elapsed

Urothelial cancer malignancy history:

Patient may have a history of resectable urothelial cancer as long as patients meet one of the following:
T0, Ta or Tis at any time
T1-4a N0 and no evidence of disease (NED) for more than 2 years from the latest therapy [e.g., radical surgery, transurethral resection of bladder tumor (TURBT), radiation, chemotherapy (neoadjuvant or adjuvant, or with radiation)]. Prior immune checkpoint inhibitor is not allowed.
Patient with history of >= pT4b, N+, and/or M1 is not eligible.
NOTE: Patients in whom concomitant or prior bladder/urethra predominant (>= 50%) urothelial carcinoma have been surgically resected and demonstrated to be only Ta or carcinoma in situ (CIS) (< cT1 N0) are eligible regardless of time elapsed
Patient must not have any uncontrolled illness including, but not limited to, ongoing or active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis [TB] testing in line with local practice), symptomatic congestive heart failure (CHF), myocardial infarction (MI) in last three months, or unstable angina pectoris, significant uncontrolled cardiac arrhythmia, clinically relevant liver cirrhosis, interstitial lung disease, or psychiatric illness/social situations that would limit compliance with study requirements
Patient must not have received prior radiation therapy to >= 25% of the bone marrow for other diseases

Patient must not have received prior systemic anthracycline therapy

NOTE: Patients who have received prior intravesical chemotherapy at any time for non-muscle invasive urothelial carcinoma of the bladder are eligible
Patient must not have either history of or active autoimmune disease requiring immunosuppressive therapy within 2 years prior to registration/randomization or any history of inflammatory bowel disease (inflammatory bowel disease [IBD], colitis, or Crohn's disease), neuromuscular autoimmune condition, immune-related pneumonitis or interstitial lung disease. Patients with well-controlled hyper/hypothyroidism, celiac controlled by diet alone, diabetes mellitus type I, vitiligo, alopecia, psoriasis, eczema, lichen planus, or similar skin/mucosa condition are eligible

Patient must not be on or have used immunosuppressive medication within 14 days prior to the first dose of durvalumab. The following are exceptions to this criterion:

Intranasal, inhaled, intra-auricular, topical steroids, or local steroid injections (e.g. intra-articular injection
Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent at the time of enrollment
Steroids as premedications for hypersensitivity reactions (e.g. computed tomography [CT] scan premedication)
Patient must not have received live attenuated vaccine within 30 days prior to the first dose of durvalumab, while on protocol treatment and within 30 days after the last dose of durvalumab

Patient must not have had a major surgical procedure within 28 days prior to registration/randomization

NOTE: Cystoscopy/ureteroscopy, stent placement or nephrostomy tube is not considered major surgery
Patient must not have history of allogenic organ transplantation

Study is for people with:

Kidney Cancer

Phase:

Phase 2

Estimated Enrollment:

249

Study ID:

NCT04628767

Recruitment Status:

Recruiting

Sponsor:

National Cancer Institute (NCI)

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 208 Locations for this study

See Locations Near You

Kingman Regional Medical Center
Kingman Arizona, 86401, United States More Info
Site Public Contact
Contact
702-384-0013
[email protected]
John A. Ellerton
Principal Investigator
Mercy Hospital Fort Smith
Fort Smith Arkansas, 72903, United States
University of Arkansas for Medical Sciences
Little Rock Arkansas, 72205, United States
Sutter Auburn Faith Hospital
Auburn California, 95602, United States More Info
Site Public Contact
Contact
[email protected]
Ari D. Baron
Principal Investigator
Alta Bates Summit Medical Center-Herrick Campus
Berkeley California, 94704, United States More Info
Site Public Contact
Contact
[email protected]
Ari D. Baron
Principal Investigator
City of Hope Comprehensive Cancer Center
Duarte California, 91010, United States More Info
Site Public Contact
Contact
800-826-4673
[email protected]
Abhishek Tripathi
Principal Investigator
Palo Alto Medical Foundation-Fremont
Fremont California, 94538, United States More Info
Site Public Contact
Contact
[email protected]
Ari D. Baron
Principal Investigator
Memorial Medical Center
Modesto California, 95355, United States More Info
Site Public Contact
Contact
[email protected]
Ari D. Baron
Principal Investigator
Palo Alto Medical Foundation-Camino Division
Mountain View California, 94040, United States More Info
Site Public Contact
Contact
[email protected]
Ari D. Baron
Principal Investigator
Palo Alto Medical Foundation Health Care
Palo Alto California, 94301, United States More Info
Site Public Contact
Contact
[email protected]
Ari D. Baron
Principal Investigator
Stanford Cancer Institute Palo Alto
Palo Alto California, 94304, United States More Info
Site Public Contact
Contact
650-498-7061
[email protected]
Ali R. Khaki
Principal Investigator
Sutter Roseville Medical Center
Roseville California, 95661, United States More Info
Site Public Contact
Contact
[email protected]
Ari D. Baron
Principal Investigator
Sutter Medical Center Sacramento
Sacramento California, 95816, United States More Info
Site Public Contact
Contact
[email protected]
Ari D. Baron
Principal Investigator
California Pacific Medical Center-Pacific Campus
San Francisco California, 94115, United States More Info
Site Public Contact
Contact
[email protected]
Ari D. Baron
Principal Investigator
Palo Alto Medical Foundation-Santa Cruz
Santa Cruz California, 95065, United States More Info
Site Public Contact
Contact
[email protected]
Ari D. Baron
Principal Investigator
Palo Alto Medical Foundation-Sunnyvale
Sunnyvale California, 94086, United States More Info
Site Public Contact
Contact
[email protected]
Ari D. Baron
Principal Investigator
Sutter Solano Medical Center/Cancer Center
Vallejo California, 94589, United States More Info
Site Public Contact
Contact
[email protected]
Ari D. Baron
Principal Investigator
UCHealth University of Colorado Hospital
Aurora Colorado, 80045, United States More Info
Site Public Contact
Contact
720-848-0650
Elizabeth R. Kessler
Principal Investigator
Poudre Valley Hospital
Fort Collins Colorado, 80524, United States More Info
Site Public Contact
Contact
970-297-6150
Elizabeth R. Kessler
Principal Investigator
Cancer Care and Hematology-Fort Collins
Fort Collins Colorado, 80528, United States More Info
Site Public Contact
Contact
[email protected]
Elizabeth R. Kessler
Principal Investigator
UCHealth Greeley Hospital
Greeley Colorado, 80631, United States More Info
Site Public Contact
Contact
[email protected]
Elizabeth R. Kessler
Principal Investigator
UCHealth Highlands Ranch Hospital
Highlands Ranch Colorado, 80129, United States More Info
Site Public Contact
Contact
720-848-0650
Elizabeth R. Kessler
Principal Investigator
Medical Center of the Rockies
Loveland Colorado, 80538, United States More Info
Site Public Contact
Contact
970-203-7083
Elizabeth R. Kessler
Principal Investigator
MedStar Washington Hospital Center
Washington District of Columbia, 20010, United States More Info
Site Public Contact
Contact
202-877-8839
Suthee Rapisuwon
Principal Investigator
Sibley Memorial Hospital
Washington District of Columbia, 20016, United States More Info
Site Public Contact
Contact
202-243-2373
[email protected]
Jean H. Hoffman-Censits
Principal Investigator
Mayo Clinic in Florida
Jacksonville Florida, 32224, United States More Info
Site Public Contact
Contact
855-776-0015
Lance C. Pagliaro
Principal Investigator
Emory University Hospital Midtown
Atlanta Georgia, 30308, United States More Info
Site Public Contact
Contact
888-946-7447
Bassel Nazha
Principal Investigator
Emory University Hospital/Winship Cancer Institute
Atlanta Georgia, 30322, United States More Info
Site Public Contact
Contact
404-778-1868
Bassel Nazha
Principal Investigator
Saint Anthony's Health
Alton Illinois, 62002, United States
Advocate Good Shepherd Hospital
Barrington Illinois, 60010, United States More Info
Site Public Contact
Contact
847-842-4847
Thomas J. Saphner
Principal Investigator
Illinois CancerCare-Bloomington
Bloomington Illinois, 61704, United States
Loyola Center for Health at Burr Ridge
Burr Ridge Illinois, 60527, United States
Illinois CancerCare-Canton
Canton Illinois, 61520, United States
Memorial Hospital of Carbondale
Carbondale Illinois, 62902, United States
SIH Cancer Institute
Carterville Illinois, 62918, United States
Illinois CancerCare-Carthage
Carthage Illinois, 62321, United States
Centralia Oncology Clinic
Centralia Illinois, 62801, United States
Advocate Illinois Masonic Medical Center
Chicago Illinois, 60657, United States More Info
Site Public Contact
Contact
773-296-5360
Thomas J. Saphner
Principal Investigator
AMG Crystal Lake - Oncology
Crystal Lake Illinois, 60014, United States More Info
Site Public Contact
Contact
630-929-6129
[email protected]
Thomas J. Saphner
Principal Investigator
Carle at The Riverfront
Danville Illinois, 61832, United States More Info
Site Public Contact
Contact
800-446-5532
[email protected]
Prem Sobti
Principal Investigator
Cancer Care Specialists of Illinois - Decatur
Decatur Illinois, 62526, United States More Info
Site Public Contact
Contact
217-876-4762
[email protected]
Bryan A. Faller
Principal Investigator
Decatur Memorial Hospital
Decatur Illinois, 62526, United States
Illinois CancerCare-Dixon
Dixon Illinois, 61021, United States
Advocate Good Samaritan Hospital
Downers Grove Illinois, 60515, United States More Info
Site Public Contact
Contact
630-275-1270
[email protected]
Thomas J. Saphner
Principal Investigator
Carle Physician Group-Effingham
Effingham Illinois, 62401, United States More Info
Site Public Contact
Contact
800-446-5532
[email protected]
Prem Sobti
Principal Investigator
Crossroads Cancer Center
Effingham Illinois, 62401, United States More Info
Site Public Contact
Contact
217-876-4762
[email protected]
Bryan A. Faller
Principal Investigator
Advocate Sherman Hospital
Elgin Illinois, 60123, United States More Info
Site Public Contact
Contact
847-429-2907
Thomas J. Saphner
Principal Investigator
Illinois CancerCare-Eureka
Eureka Illinois, 61530, United States
Illinois CancerCare-Galesburg
Galesburg Illinois, 61401, United States
Western Illinois Cancer Treatment Center
Galesburg Illinois, 61401, United States
Advocate South Suburban Hospital
Hazel Crest Illinois, 60429, United States More Info
Site Public Contact
Contact
708-799-9995
Thomas J. Saphner
Principal Investigator
Loyola Medicine Homer Glen
Homer Glen Illinois, 60491, United States
Illinois CancerCare-Kewanee Clinic
Kewanee Illinois, 61443, United States
AMG Libertyville - Oncology
Libertyville Illinois, 60048, United States
Illinois CancerCare-Macomb
Macomb Illinois, 61455, United States
Carle Physician Group-Mattoon/Charleston
Mattoon Illinois, 61938, United States More Info
Site Public Contact
Contact
800-446-5532
[email protected]
Prem Sobti
Principal Investigator
Loyola University Medical Center
Maywood Illinois, 60153, United States
Marjorie Weinberg Cancer Center at Loyola-Gottlieb
Melrose Park Illinois, 60160, United States
Good Samaritan Regional Health Center
Mount Vernon Illinois, 62864, United States
Cancer Care Center of O'Fallon
O'Fallon Illinois, 62269, United States More Info
Site Public Contact
Contact
217-876-4762
[email protected]
Bryan A. Faller
Principal Investigator
Advocate Christ Medical Center
Oak Lawn Illinois, 60453, United States More Info
Site Public Contact
Contact
800-323-8622
Thomas J. Saphner
Principal Investigator
Illinois CancerCare-Ottawa Clinic
Ottawa Illinois, 61350, United States
Advocate Lutheran General Hospital
Park Ridge Illinois, 60068, United States More Info
Site Public Contact
Contact
847-384-3621
Thomas J. Saphner
Principal Investigator
Illinois CancerCare-Pekin
Pekin Illinois, 61554, United States
Illinois CancerCare-Peoria
Peoria Illinois, 61615, United States
Methodist Medical Center of Illinois
Peoria Illinois, 61636, United States
Illinois CancerCare-Peru
Peru Illinois, 61354, United States
Valley Radiation Oncology
Peru Illinois, 61354, United States
Illinois CancerCare-Princeton
Princeton Illinois, 61356, United States
Southern Illinois University School of Medicine
Springfield Illinois, 62702, United States More Info
Site Public Contact
Contact
217-545-7929
Bryan A. Faller
Principal Investigator
Springfield Clinic
Springfield Illinois, 62702, United States More Info
Site Public Contact
Contact
800-444-7541
Bryan A. Faller
Principal Investigator
Memorial Medical Center
Springfield Illinois, 62781, United States
Carle Cancer Center
Urbana Illinois, 61801, United States More Info
Site Public Contact
Contact
800-446-5532
[email protected]
Prem Sobti
Principal Investigator
Illinois CancerCare - Washington
Washington Illinois, 61571, United States
Reid Health
Richmond Indiana, 47374, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Mary Greeley Medical Center
Ames Iowa, 50010, United States
McFarland Clinic - Ames
Ames Iowa, 50010, United States
University of Iowa Healthcare Cancer Services Quad Cities
Bettendorf Iowa, 52722, United States More Info
Site Public Contact
Contact
563-355-7733
[email protected]
Yousef Zakharia
Principal Investigator
McFarland Clinic - Boone
Boone Iowa, 50036, United States
McFarland Clinic - Trinity Cancer Center
Fort Dodge Iowa, 50501, United States
University of Iowa/Holden Comprehensive Cancer Center
Iowa City Iowa, 52242, United States More Info
Site Public Contact
Contact
800-237-1225
Yousef Zakharia
Principal Investigator
McFarland Clinic - Jefferson
Jefferson Iowa, 50129, United States
McFarland Clinic - Marshalltown
Marshalltown Iowa, 50158, United States
Central Care Cancer Center - Garden City
Garden City Kansas, 67846, United States
Central Care Cancer Center - Great Bend
Great Bend Kansas, 67530, United States
University of Kentucky/Markey Cancer Center
Lexington Kentucky, 40536, United States More Info
Site Public Contact
Contact
859-257-3379
Patrick J. Hensley
Principal Investigator
East Jefferson General Hospital
Metairie Louisiana, 70006, United States More Info
Site Public Contact
Contact
504-210-3539
[email protected]
Scott E. Delacroix
Principal Investigator
LSU Healthcare Network / Metairie Multi-Specialty Clinic
Metairie Louisiana, 70006, United States More Info
Site Public Contact
Contact
504-210-3539
[email protected]
Scott E. Delacroix
Principal Investigator
Harold Alfond Center for Cancer Care
Augusta Maine, 04330, United States More Info
Site Public Contact
Contact
207-626-4855
Lindsey Hathaway
Principal Investigator
MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford
Biddeford Maine, 04005, United States More Info
Site Public Contact
Contact
[email protected]
Lindsey Hathaway
Principal Investigator
MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford
Sanford Maine, 04073, United States More Info
Site Public Contact
Contact
[email protected]
Lindsey Hathaway
Principal Investigator
Maine Medical Partners - South Portland
South Portland Maine, 04106, United States More Info
Site Public Contact
Contact
207-396-8670
[email protected]
Lindsey Hathaway
Principal Investigator
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore Maryland, 21287, United States More Info
Site Public Contact
Contact
410-955-8804
[email protected]
Jean H. Hoffman-Censits
Principal Investigator
UMass Memorial Medical Center - University Campus
Worcester Massachusetts, 01655, United States More Info
Site Public Contact
Contact
508-856-3216
[email protected]
Kriti Mittal
Principal Investigator
Saint Joseph Mercy Hospital
Ann Arbor Michigan, 48106, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Elie G. Dib
Principal Investigator
Saint Joseph Mercy Brighton
Brighton Michigan, 48114, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Elie G. Dib
Principal Investigator
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton Michigan, 48114, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Elie G. Dib
Principal Investigator
Saint Joseph Mercy Canton
Canton Michigan, 48188, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Elie G. Dib
Principal Investigator
Trinity Health IHA Medical Group Hematology Oncology - Canton
Canton Michigan, 48188, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Elie G. Dib
Principal Investigator
Saint Joseph Mercy Chelsea
Chelsea Michigan, 48118, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Elie G. Dib
Principal Investigator
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Chelsea Michigan, 48118, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Elie G. Dib
Principal Investigator
Hematology Oncology Consultants-Clarkston
Clarkston Michigan, 48346, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Elie G. Dib
Principal Investigator
Newland Medical Associates-Clarkston
Clarkston Michigan, 48346, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Elie G. Dib
Principal Investigator
Genesee Cancer and Blood Disease Treatment Center
Flint Michigan, 48503, United States More Info
Site Public Contact
Contact
810-762-8038
[email protected]
Elie G. Dib
Principal Investigator
Genesee Hematology Oncology PC
Flint Michigan, 48503, United States More Info
Site Public Contact
Contact
810-762-8038
[email protected]
Elie G. Dib
Principal Investigator
Genesys Hurley Cancer Institute
Flint Michigan, 48503, United States More Info
Site Public Contact
Contact
810-762-8038
[email protected]
Elie G. Dib
Principal Investigator
Hope Cancer Clinic
Livonia Michigan, 48154, United States
Trinity Health Saint Mary Mercy Livonia Hospital
Livonia Michigan, 48154, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Elie G. Dib
Principal Investigator
Great Lakes Cancer Management Specialists-Macomb Medical Campus
Macomb Michigan, 48044, United States More Info
Site Public Contact
Contact
313-343-3166
[email protected]
Elie G. Dib
Principal Investigator
21st Century Oncology-Pontiac
Pontiac Michigan, 48341, United States More Info
Site Public Contact
Contact
248-858-6215
[email protected]
Elie G. Dib
Principal Investigator
Newland Medical Associates-Pontiac
Pontiac Michigan, 48341, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Elie G. Dib
Principal Investigator
Saint Joseph Mercy Oakland
Pontiac Michigan, 48341, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Elie G. Dib
Principal Investigator
Huron Gastroenterology PC
Ypsilanti Michigan, 48106, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Elie G. Dib
Principal Investigator
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Ypsilanti Michigan, 48197, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Elie G. Dib
Principal Investigator
Fairview Ridges Hospital
Burnsville Minnesota, 55337, United States
Minnesota Oncology - Burnsville
Burnsville Minnesota, 55337, United States
Cambridge Medical Center
Cambridge Minnesota, 55008, United States
Mercy Hospital
Coon Rapids Minnesota, 55433, United States More Info
Site Public Contact
Contact
952-993-1517
[email protected]
David M. King
Principal Investigator
Fairview Southdale Hospital
Edina Minnesota, 55435, United States
Unity Hospital
Fridley Minnesota, 55432, United States
Fairview Clinics and Surgery Center Maple Grove
Maple Grove Minnesota, 55369, United States
Minnesota Oncology Hematology PA-Maplewood
Maplewood Minnesota, 55109, United States More Info
Site Public Contact
Contact
952-993-1517
[email protected]
David M. King
Principal Investigator
Saint John's Hospital - Healtheast
Maplewood Minnesota, 55109, United States
Abbott-Northwestern Hospital
Minneapolis Minnesota, 55407, United States
Hennepin County Medical Center
Minneapolis Minnesota, 55415, United States
Health Partners Inc
Minneapolis Minnesota, 55454, United States
Monticello Cancer Center
Monticello Minnesota, 55362, United States
New Ulm Medical Center
New Ulm Minnesota, 56073, United States
Fairview Northland Medical Center
Princeton Minnesota, 55371, United States
North Memorial Medical Health Center
Robbinsdale Minnesota, 55422, United States
Mayo Clinic in Rochester
Rochester Minnesota, 55905, United States More Info
Site Public Contact
Contact
855-776-0015
Lance C. Pagliaro
Principal Investigator
Park Nicollet Clinic - Saint Louis Park
Saint Louis Park Minnesota, 55416, United States
Regions Hospital
Saint Paul Minnesota, 55101, United States More Info
Site Public Contact
Contact
952-993-1517
[email protected]
David M. King
Principal Investigator
United Hospital
Saint Paul Minnesota, 55102, United States
Saint Francis Regional Medical Center
Shakopee Minnesota, 55379, United States
Lakeview Hospital
Stillwater Minnesota, 55082, United States
Ridgeview Medical Center
Waconia Minnesota, 55387, United States
Rice Memorial Hospital
Willmar Minnesota, 56201, United States
Minnesota Oncology Hematology PA-Woodbury
Woodbury Minnesota, 55125, United States
Fairview Lakes Medical Center
Wyoming Minnesota, 55092, United States
Saint Louis Cancer and Breast Institute-Ballwin
Ballwin Missouri, 63011, United States
Central Care Cancer Center - Bolivar
Bolivar Missouri, 65613, United States
Saint Francis Medical Center
Cape Girardeau Missouri, 63703, United States More Info
Site Public Contact
Contact
573-334-2230
[email protected]
Bryan A. Faller
Principal Investigator
Southeast Cancer Center
Cape Girardeau Missouri, 63703, United States
Parkland Health Center - Farmington
Farmington Missouri, 63640, United States
Capital Region Southwest Campus
Jefferson City Missouri, 65109, United States
Freeman Health System
Joplin Missouri, 64804, United States
Mercy Hospital Joplin
Joplin Missouri, 64804, United States
Delbert Day Cancer Institute at PCRMC
Rolla Missouri, 65401, United States
Mercy Clinic-Rolla-Cancer and Hematology
Rolla Missouri, 65401, United States
Heartland Regional Medical Center
Saint Joseph Missouri, 64506, United States
Saint Louis Cancer and Breast Institute-South City
Saint Louis Missouri, 63109, United States
Mercy Hospital South
Saint Louis Missouri, 63128, United States
Missouri Baptist Medical Center
Saint Louis Missouri, 63131, United States
Mercy Hospital Saint Louis
Saint Louis Missouri, 63141, United States More Info
Site Public Contact
Contact
314-251-7066
Jay W. Carlson
Principal Investigator
Sainte Genevieve County Memorial Hospital
Sainte Genevieve Missouri, 63670, United States
Mercy Hospital Springfield
Springfield Missouri, 65804, United States
CoxHealth South Hospital
Springfield Missouri, 65807, United States
Missouri Baptist Sullivan Hospital
Sullivan Missouri, 63080, United States
BJC Outpatient Center at Sunset Hills
Sunset Hills Missouri, 63127, United States
Mercy Hospital Washington
Washington Missouri, 63090, United States
OptumCare Cancer Care at Seven Hills
Henderson Nevada, 89052, United States More Info
Site Public Contact
Contact
702-384-0013
[email protected]
John A. Ellerton
Principal Investigator
OptumCare Cancer Care at Charleston
Las Vegas Nevada, 89102, United States More Info
Site Public Contact
Contact
702-384-0013
[email protected]
John A. Ellerton
Principal Investigator
OptumCare Cancer Care at Fort Apache
Las Vegas Nevada, 89148, United States More Info
Site Public Contact
Contact
702-384-0013
[email protected]
John A. Ellerton
Principal Investigator
Hackensack University Medical Center
Hackensack New Jersey, 07601, United States More Info
Site Public Contact
Contact
201-996-2879
Robert S. Alter
Principal Investigator
Saint Barnabas Medical Center
Livingston New Jersey, 07039, United States
Rutgers Cancer Institute of New Jersey
New Brunswick New Jersey, 08903, United States More Info
Site Public Contact
Contact
732-235-7356
Saum B. Ghodoussipour
Principal Investigator
University of New Mexico Cancer Center
Albuquerque New Mexico, 87102, United States More Info
Site Public Contact
Contact
505-925-0348
[email protected]
Jude Khatib
Principal Investigator
Roswell Park Cancer Institute
Buffalo New York, 14263, United States
Southeastern Medical Oncology Center-Clinton
Clinton North Carolina, 28328, United States More Info
Site Public Contact
Contact
919-587-9084
[email protected]
Samer S. Kasbari
Principal Investigator
Southeastern Medical Oncology Center-Goldsboro
Goldsboro North Carolina, 27534, United States More Info
Site Public Contact
Contact
919-587-9084
[email protected]
Samer S. Kasbari
Principal Investigator
Southeastern Medical Oncology Center-Jacksonville
Jacksonville North Carolina, 28546, United States More Info
Site Public Contact
Contact
910-587-9084
[email protected]
Samer S. Kasbari
Principal Investigator
Wake Forest University Health Sciences
Winston-Salem North Carolina, 27157, United States More Info
Site Public Contact
Contact
336-713-6771
Michael McCormack
Principal Investigator
Dayton Physicians LLC-Miami Valley South
Centerville Ohio, 45459, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Miami Valley Hospital South
Centerville Ohio, 45459, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Tarek M. Sabagh
Principal Investigator
Dayton Blood and Cancer Center
Dayton Ohio, 45409, United States More Info
Site Public Contact
Contact
937-276-8320
Tarek M. Sabagh
Principal Investigator
Miami Valley Hospital
Dayton Ohio, 45409, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Tarek M. Sabagh
Principal Investigator
Dayton Physician LLC-Miami Valley Hospital North
Dayton Ohio, 45415, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Miami Valley Hospital North
Dayton Ohio, 45415, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Tarek M. Sabagh
Principal Investigator
Armes Family Cancer Center
Findlay Ohio, 45840, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Atrium Medical Center-Middletown Regional Hospital
Franklin Ohio, 45005, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Tarek M. Sabagh
Principal Investigator
Dayton Physicians LLC-Atrium
Franklin Ohio, 45005, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Miami Valley Cancer Care and Infusion
Greenville Ohio, 45331, United States More Info
Site Public Contact
Contact
937-569-7515
Tarek M. Sabagh
Principal Investigator
Greater Dayton Cancer Center
Kettering Ohio, 45409, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Kettering Medical Center
Kettering Ohio, 45429, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Howard M. Gross
Principal Investigator
Springfield Regional Cancer Center
Springfield Ohio, 45504, United States
Upper Valley Medical Center
Troy Ohio, 45373, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Tarek M. Sabagh
Principal Investigator
Cancer Centers of Southwest Oklahoma Research
Lawton Oklahoma, 73505, United States More Info
Site Public Contact
Contact
877-231-4440
Adanma Anji Ayanambakkam Attanathi
Principal Investigator
University of Oklahoma Health Sciences Center
Oklahoma City Oklahoma, 73104, United States More Info
Site Public Contact
Contact
405-271-8777
[email protected]
Adanma Anji Ayanambakkam Attanathi
Principal Investigator
Mercy Hospital Oklahoma City
Oklahoma City Oklahoma, 73120, United States
UPMC Hillman Cancer Center Erie
Erie Pennsylvania, 16505, United States More Info
Site Public Contact
Contact
412-389-5208
[email protected]
Priyanka V. Chablani
Principal Investigator
UPMC Cancer Centers - Arnold Palmer Pavilion
Greensburg Pennsylvania, 15601, United States More Info
Site Public Contact
Contact
724-838-1900
Priyanka V. Chablani
Principal Investigator
Penn State Milton S Hershey Medical Center
Hershey Pennsylvania, 17033, United States More Info
Site Public Contact
Contact
717-531-3779
[email protected]
Monika Joshi
Principal Investigator
UPMC Hillman Cancer Center - Monroeville
Monroeville Pennsylvania, 15146, United States More Info
Site Public Contact
Contact
412-389-5208
[email protected]
Priyanka V. Chablani
Principal Investigator
University of Pennsylvania/Abramson Cancer Center
Philadelphia Pennsylvania, 19104, United States More Info
Site Public Contact
Contact
800-474-9892
Ronac Mamtani
Principal Investigator
Thomas Jefferson University Hospital
Philadelphia Pennsylvania, 19107, United States More Info
Site Public Contact
Contact
215-600-9151
[email protected]
William J. Tester
Principal Investigator
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh Pennsylvania, 15232, United States More Info
Site Public Contact
Contact
412-647-8073
Priyanka V. Chablani
Principal Investigator
UPMC-Passavant Hospital
Pittsburgh Pennsylvania, 15237, United States More Info
Site Public Contact
Contact
412-367-6454
Priyanka V. Chablani
Principal Investigator
UPMC-Saint Clair Hospital Cancer Center
Pittsburgh Pennsylvania, 15243, United States More Info
Site Public Contact
Contact
412-502-3920
Priyanka V. Chablani
Principal Investigator
UPMC Cancer Center-Washington
Washington Pennsylvania, 15301, United States More Info
Site Public Contact
Contact
[email protected]
Priyanka V. Chablani
Principal Investigator
Medical University of South Carolina
Charleston South Carolina, 29425, United States
Parkland Memorial Hospital
Dallas Texas, 75235, United States More Info
Site Public Contact
Contact
214-590-5582
[email protected]
Vitaly Margulis
Principal Investigator
UT Southwestern Simmons Cancer Center - RedBird
Dallas Texas, 75237, United States More Info
Site Public Contact
Contact
214-648-7097
[email protected]
Vitaly Margulis
Principal Investigator
UT Southwestern/Simmons Cancer Center-Dallas
Dallas Texas, 75390, United States More Info
Site Public Contact
Contact
214-648-7097
[email protected]
Vitaly Margulis
Principal Investigator
UT Southwestern/Simmons Cancer Center-Fort Worth
Fort Worth Texas, 76104, United States More Info
Site Public Contact
Contact
214-648-7097
[email protected]
Vitaly Margulis
Principal Investigator
UT Southwestern Clinical Center at Richardson/Plano
Richardson Texas, 75080, United States More Info
Site Public Contact
Contact
972-669-7044
[email protected]
Vitaly Margulis
Principal Investigator
FHCC South Lake Union
Seattle Washington, 98109, United States More Info
Site Public Contact
Contact
800-804-8824
Petros Grivas
Principal Investigator
Fred Hutchinson Cancer Research Center
Seattle Washington, 98109, United States More Info
Site Public Contact
Contact
800-804-8824
Petros Grivas
Principal Investigator
University of Washington Medical Center - Montlake
Seattle Washington, 98195, United States More Info
Site Public Contact
Contact
800-804-8824
Petros Grivas
Principal Investigator
ThedaCare Regional Cancer Center
Appleton Wisconsin, 54911, United States More Info
Site Public Contact
Contact
920-364-3604
[email protected]
Harsha V. Poola
Principal Investigator
Aurora Cancer Care-Southern Lakes VLCC
Burlington Wisconsin, 53105, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Thomas J. Saphner
Principal Investigator
Marshfield Medical Center-EC Cancer Center
Eau Claire Wisconsin, 54701, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Seth O. Fagbemi
Principal Investigator
Aurora Health Care Germantown Health Center
Germantown Wisconsin, 53022, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Thomas J. Saphner
Principal Investigator
Aurora Cancer Care-Grafton
Grafton Wisconsin, 53024, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Thomas J. Saphner
Principal Investigator
Aurora BayCare Medical Center
Green Bay Wisconsin, 54311, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Thomas J. Saphner
Principal Investigator
Aurora Cancer Care-Kenosha South
Kenosha Wisconsin, 53142, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Thomas J. Saphner
Principal Investigator
Aurora Bay Area Medical Group-Marinette
Marinette Wisconsin, 54143, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Thomas J. Saphner
Principal Investigator
Marshfield Medical Center-Marshfield
Marshfield Wisconsin, 54449, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Seth O. Fagbemi
Principal Investigator
Aurora Cancer Care-Milwaukee
Milwaukee Wisconsin, 53209, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Thomas J. Saphner
Principal Investigator
Aurora Saint Luke's Medical Center
Milwaukee Wisconsin, 53215, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Thomas J. Saphner
Principal Investigator
Aurora Sinai Medical Center
Milwaukee Wisconsin, 53233, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Thomas J. Saphner
Principal Investigator
Marshfield Clinic-Minocqua Center
Minocqua Wisconsin, 54548, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Seth O. Fagbemi
Principal Investigator
ProHealth D N Greenwald Center
Mukwonago Wisconsin, 53149, United States More Info
Site Public Contact
Contact
[email protected]
Timothy R. Wassenaar
Principal Investigator
Cancer Center of Western Wisconsin
New Richmond Wisconsin, 54017, United States
ProHealth Oconomowoc Memorial Hospital
Oconomowoc Wisconsin, 53066, United States More Info
Site Public Contact
Contact
262-928-7878
Timothy R. Wassenaar
Principal Investigator
Vince Lombardi Cancer Clinic - Oshkosh
Oshkosh Wisconsin, 54904, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Thomas J. Saphner
Principal Investigator
Aurora Cancer Care-Racine
Racine Wisconsin, 53406, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Thomas J. Saphner
Principal Investigator
Marshfield Medical Center-Rice Lake
Rice Lake Wisconsin, 54868, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Seth O. Fagbemi
Principal Investigator
Vince Lombardi Cancer Clinic-Sheboygan
Sheboygan Wisconsin, 53081, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Thomas J. Saphner
Principal Investigator
Marshfield Medical Center-River Region at Stevens Point
Stevens Point Wisconsin, 54482, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Seth O. Fagbemi
Principal Investigator
Aurora Medical Center in Summit
Summit Wisconsin, 53066, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Thomas J. Saphner
Principal Investigator
Vince Lombardi Cancer Clinic-Two Rivers
Two Rivers Wisconsin, 54241, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Thomas J. Saphner
Principal Investigator
ProHealth Waukesha Memorial Hospital
Waukesha Wisconsin, 53188, United States More Info
Site Public Contact
Contact
262-928-7632
Timothy R. Wassenaar
Principal Investigator
UW Cancer Center at ProHealth Care
Waukesha Wisconsin, 53188, United States More Info
Site Public Contact
Contact
262-928-5539
[email protected]
Timothy R. Wassenaar
Principal Investigator
ThedaCare Cancer Care - Waupaca
Waupaca Wisconsin, 54981, United States More Info
Site Public Contact
Contact
920-364-3605
[email protected]
Harsha V. Poola
Principal Investigator
Aurora Cancer Care-Milwaukee West
Wauwatosa Wisconsin, 53226, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Thomas J. Saphner
Principal Investigator
Aurora West Allis Medical Center
West Allis Wisconsin, 53227, United States More Info
Site Public Contact
Contact
414-302-2304
[email protected]
Thomas J. Saphner
Principal Investigator
Marshfield Medical Center - Weston
Weston Wisconsin, 54476, United States More Info
Site Public Contact
Contact
800-782-8581
[email protected]
Seth O. Fagbemi
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Kidney Cancer

Phase:

Phase 2

Estimated Enrollment:

249

Study ID:

NCT04628767

Recruitment Status:

Recruiting

Sponsor:


National Cancer Institute (NCI)

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.